mp.weixin.qq.com·· 17 hours agoPickScore77
Gilead Signs Definitive Agreement to Acquire PepStar Therapeutics' HCXT-2001 for $1.275 Billion Upfront
In brief
Gilead has signed a definitive agreement to acquire an oral IL-23R inhibitor program from PepStar Therapeutics for an upfront payment of $1.275 billion, with HCXT-2001 as the core asset. The drug is still in Phase I trials, the upfront payment equals about 8.5 billion RMB, and PepStar Therapeutics was founded a little over three years ago.
Why it matters
HCXT-2001 is still in Phase I yet drew a $1.275 billion upfront payment, letting readers gauge early-stage asset pricing.
Source: mp.weixin.qq.com · mp.weixin.qq.com